Summit Therapeutics Inc（SMMT）：截至2026年06月30日止三个月的季度财报（10-Q）（英文版）（72页）.pdf

1、UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549_FORM 10-Q_(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30,2026orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT

2、OF 1934 For thetransition period from _ to _Commission File Number:001-36866_Summit Therapeutics Inc.(Exact name of registrant as specified in its charter)_Delaware37-1979717(State or other jurisdiction ofincorporation or organization)(I.R.S.Employer IdentificationNo.)601 Brickell Key Drive,Suite 10

3、00,Miami,FL(Address of principal executive offices)33131(Zip Code)305-203-2034(Registrants telephone number,including area code)Not Applicable(Former name or former address and former fiscal year,if changed since last report)_Securities registered pursuant to Section 12(b)of the Act:Title of each cl

4、assTrading Symbol(s)Name of each exchange on which registeredCommon Stock,$0.01 par value per shareSMMTThe Nasdaq Stock Market LLCIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the precedin

5、g 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject tosuch filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted

6、pursuant to Rule405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required tosubmit such files).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer